Abstract
Antibacterial therapy of community-acquired bacterial meningitis in children is changing worldwide, and 1 currently recommended option includes the use of meropenem as monotherapy. Data presented at a Zeneca-sponsored symposium at the 9th European Congress of Clinical Microbiology and Infectious Diseases [ Berlin, Germany; March 1999 ] confirmed the efficacy and favourable safety profile of meropenem in children with bacterial meningitis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have